Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Pembrolizumab + Chemotherapy in Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
NCT04662710Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of lenvatinib and pembrolizumab in gastroesophageal adenocarcinoma (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 21 days, Number of Participants With Adverse Events at 44 months and 5 more. Started Dec 2020; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT04662710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662710.